Redmile Group disclosed a buy of 1,316,390 shares of Scholar Rock Holding Corporation (NASDAQ:SRRK) in a February 17, 2026, SEC filing, with the estimated transaction value at $49.37 million based on quarterly average pricing.

According to a SEC filing dated February 17, 2026, Redmile Group, LLC increased its position in Scholar Rock Holding Corporation by 1,316,390 shares during the fourth quarter. The estimated trade size was $49.37 million based on the average share price for the quarter. The quarter-end value of the position increased by $84.58 million, which reflects both the additional shares acquired and the impact of market price movements.

• Redmile Group’s buy lifts its stake in Scholar Rock Holding Corporation to 16.94% of the fund’s 13F reportable assets under management.

• Top holdings after the filing:

  • NASDAQ:SRRK: $229.98 million (16.9% of AUM)

  • NASDAQ:KRYS: $167.08 million (12.3% of AUM)

  • NASDAQ:NRIX: $153.54 million (11.3% of AUM)

  • NASDAQ:STOK: $128.04 million (9.4% of AUM)

  • NASDAQ:IMNM: $122.83 million (9.0% of AUM)

• As of February 17, 2026, shares of Scholar Rock Holding Corporation were priced at $46.45, up 25.7% over the past year and outperforming the S&P 500 by 13.39 percentage points.

• Scholar Rock Holding develops biopharmaceutical products targeting serious diseases, including Apitegromab for spinal muscular atrophy and SRK-181 for cancer therapy resistance.

• The firm operates a research-driven model focused on discovering and advancing protein growth factor inhibitors, with revenue potential from product commercialization and strategic collaborations.

• It serves patients with neuromuscular disorders, cancer, and fibrotic diseases, targeting healthcare providers and biopharmaceutical partners.

Scholar Rock Holding Corporation is a clinical-stage biotechnology company specializing in the discovery and development of therapies that modulate protein growth factor signaling. The company leverages a proprietary platform to address unmet medical needs in neuromuscular, oncological, and fibrotic indications. Strategic collaborations and a focused pipeline position Scholar Rock to capitalize on innovative science in high-impact therapeutic areas.

This purchase signals a willingness to lean into that volatility rather than trim around it. Scholar Rock enters 2026 with a clear catalyst path. According to an announcement last month, the company plans a Biologics License Application resubmission for apitegromab in spinal muscular atrophy and anticipates a potential U.S. launch following approval this year. It also has approximately $365 million in cash as of December 31, with runway projected into 2027. That balance sheet reduces near-term dilution risk, a key consideration for long-term biotech investors.

Unlike diversified portfolios, this fund concentrates heavily in clinical-stage names. Scholar Rock now represents roughly 17% of assets, alongside other high-conviction biotech positions. That concentration amplifies both upside and binary risk.

Shares are up about 26% over the past year, modestly beating the broader market and suggesting investors are already assigning value to regulatory progress and pipeline depth. Beyond apitegromab, programs in FSHD and the SRK-439 myostatin inhibitor expand optionality.

Before you buy stock in Scholar Rock, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Scholar Rock wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you’d have $424,262!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $1,163,635!*

Now, it’s worth noting Stock Advisor’s total average return is 904% — a market-crushing outperformance compared to 194% for the S&P 500. Don’t miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of February 22, 2026.

Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Krystal Biotech. The Motley Fool has a disclosure policy.

Biotech Fund Doubles Down With $49 Million Scholar Rock Buy as Shares Climb 26% was originally published by The Motley Fool